Antihypertensive therapy in male and female: are there sex differences in choice of drugs?
https://doi.org/10.18087/cardio.2566
Abstract
Tis review presents data on prevalence, control, and effectiveness of treatment of hypertension in male and female. Te features of protective action and manifestations of undesirable effects of antihypertensive therapy in male and female, as well as situations influencing the choice of a drug depending on sex are discussed.
About the Authors
V. N. Larina
Pirogov Russian National Research Medical University
Russian Federation
Russian Federation
Ostrovityanova 1, Moscow 117997
D. A. Orlov
Pirogov Russian National Research Medical University
Russian Federation
Russian Federation
Ostrovityanova 1, Moscow 117997
References
1. Doumas M, Papademetriou V, Faselis C, Kokkinos P. Gender Differences in Hypertension: Myths and Reality. Current Hypertension Reports. 2013;15(4):321–30. DOI: 10.1007/s11906-013-0359-y
2. Pimenta E. Hypertension in women. Hypertension Research. 2012;35(2):148–52. DOI: 10.1038/hr.2011.190
3. Forouzanfar MH, Liu P, Roth GA, Ng M, Biryukov S, Marczak L et al. Global Burden of Hypertension and Systolic Blood Pressure of at Least 110 to 115 mm Hg, 1990-2015. JAMA. 2017;317(2):165. DOI: 10.1001/jama.2016.19043
4. Wolf-Maier K. Hypertension Prevalence and Blood Pressure Levels in 6 European Countries, Canada, and the United States. JAMA. 2003;289(18):2363. DOI: 10.1001/jama.289.18.2363
5. Boytsov S. A., Balanova Yu. A., Shalnova S. A., Deev A. D., Artamonova G. V., Gatagonova T. M. et al. Arterial hypertension among individuals of 25-64 years old: prevalence, awareness, treatment and control. By the data from ECCD. Cardiovascular Terapy and Prevention. 2014;13(4):4-14.
6. Townsend N, Wilson L, Bhatnagar P, Wickramasinghe K, Rayner M, Nichols M. Cardiovascular disease in Europe: epidemiological update 2016. European Heart Journal. 2016;37(42):3232–45. DOI: 10.1093/eurheartj/ehw334
7. Hsia J, Margolis KL, Eaton CB, Wenger NK, Allison M, Wu L et al. Prehypertension and Cardiovascular Disease Risk in the Women’s Health Initiative. Circulation. 2007;115(7):855–60. DOI: 10.1161/CIRCULATIONAHA.106.656850
8. Nichols M, Townsend N, Scarborough P, Rayner M. European cardiovascular disease statistics. 128 p. ISBN 978-2-9537898-1-2
9. Roger VL, Go AS, Lloyd-Jones DM, Adams RJ, Berry JD, Brown TM et al. Heart Disease and Stroke Statistics—2011 Update: A Report from the American Heart Association. Circulation. 2011;123(4):e18– 209. DOI: 10.1161/CIR.0b013e3182009701
10. Chazova I. E., Oschepkova E. V. Results of the Federal (National) Project for prevention and treatment essential hypertension patients in Russia from 2002-2012 years. Annals of the Russian academy of medical sciences. 2013;68(2):4-11. DOI: 10.15690/vramn.v68i2.542
11. Glezer M. G., Karpov Yu. A. Te program FORTISSIMO: evaluation of efcacy and safety Noliprel A B-forte in the treatment of hypertension of men and women. Women’s health problems. 2013;8(3):5-15.
12. Katsi V, Kallistratos MS, Kontoangelos K, Sakkas P, Souliotis K, Tsioufs C et al. Arterial Hypertension and Health-Related Quality of Life. Frontiers in Psychiatry. 2017;8. DOI: 10.3389/fpsyt.2017.00270
13. Grinshtein Yu. I., Petrova M. M., Shabalin V. V., Ruf R. R., Balanova Yu. A., Evstifeeva S. E. et al. Te prevalence of arterial hypertension in krasnoyarsky territory: the data from the epidemiology study ESSE-RF. Arterial hypertension. 2016;22(6):551-9.
14. Hajar R. Framingham contribution to cardiovascular disease. Heart Views. 2016;17(2):78. DOI: 10.4103/1995-705X.185130
15. Etehad D, Emdin CA, Kiran A, Anderson SG, Callender T, Emberson J et al. Blood pressure lowering for prevention of cardiovascular disease and death: a systematic review and meta-analysis. Te Lancet. 2016;387(10022):957–67. DOI: 10.1016/S0140-6736(15)01225-8
16. Deborde T, Amar L, Bobrie G, Postel-Vinay N, Bataglia C, Tache A et al. Sex differences in antihypertensive treatment in France among 17 856 patients in a tertiary hypertension unit: Journal of Hypertension. 2018;36(4):939–46. DOI: 10.1097/HJH.0000000000001607
17. Hansen TW, Kikuya M, Tijs L, Li Y, Boggia J, Björklund-Bodegârd K et al. Diagnostic thresholds for ambulatory blood pressure moving lower: a review based on a meta-analysis-clinical implications. Journal of Clinical Hypertension (Greenwich, Conn.). 2008;10(5):377–81. PMID: 18453797
18. Chazova I. E., Fomin V. V., Razuvaeva M. A., Vigdorchik A. V. Epidemiological characteristics of resistant and uncontrolled arterial hypertension in the Russian Federation the all-Russian register of uncontrolled and resistant hypertension REGATA-PRIMA (Resistant arterial Hypertension – the causes and mechanisms of development). Systemic Hypertension. 2010;3:34-41.
19. Coylewright M, Reckelhoff JF, Ouyang P. Menopause and Hypertension: An Age-Old Debate. Hypertension. 2008;51(4):952–9. DOI: 10.1161/HYPERTENSIONAHA.107.105742
20. Dubey RK, Oparil S, Imthurn B, Jackson EK. Sex hormones and hypertension. Cardiovascular Research. 2002;53(3):688–708. PMID: 11861040
21. Bălan H, Popescu L. ‘Gender specifc medicine’: a focus on genderdifferences in hypertension. Romanian Journal of Internal Medicine = Revue Roumaine De Medecine Interne. 2014;52(3):129–41. PMID: 25509556
22. Ulubieva E. A., Avtandilov A. G., Puhaeva A. A., Libov I. A. Smoking and menopause. Structural functional changes of the arteries in women. Problem of women health. 2016; 2(11):22-7.
23. Giralt D, Domingues-Montanari S, Mendioroz M, Ortega L, Maisterra O, Perea-Gainza M et al. Te gender gap in stroke: a meta-analysis: Gender differences in ischemic stroke. Acta Neurologica Scandinavica. 2012;125(2):83–90. DOI: 10.1111/j.1600-0404.2011.01514.x
24. Kouvari M, Panagiotakos DB, Chrysohoou C, Georgousopoulou E, Notara V, Tousoulis D et al. Gender-specifc, Lifestyle-related Factors and 10-year Cardiovascular Disease Risk; the ATICA and GREECS Cohort Studies. Current Vascular Pharmacology. 2018; DOI: 10.2174/1570161116666180608121720
25. Song S, Kim J, Kim J. Gender Differences in the Association between Dietary Patern and the Incidence of Hypertension in MiddleAged and Older Adults. Nutrients. 2018;10(2):252. DOI: 10.3390/nu10020252
26. Reckelhoff JF. Gender differences in hypertension: Current Opinion in Nephrology and Hypertension. 2018;1. DOI: 10.1097/MNH.0000000000000404
27. Rosano GMC, Lewis B, Agewall S, Wassmann S, Vitale C, Schmidt H et al. Gender differences in the effect of cardiovascular drugs: a position document of the Working Group on Pharmacology and Drug Terapy of the ESC: Figure 1. European Heart Journal. 2015;36(40):2677–80. DOI: 10.1093/eurheartj/ehv161
28. Scot PE, Unger EF, Jenkins MR, Southworth MR, McDowell T-Y, Geller RJ et al. Participation of Women in Clinical Trials Supporting FDA Approval of Cardiovascular Drugs. Journal of the American College of Cardiology. 2018;71(18):1960–9. DOI: 10.1016/j.jacc.2018.02.070
29. Williams B, Mancia G, Spiering W, Agabiti Rosei E, Azizi M, Burnier M et al. 2018 ESC/ESH Guidelines for the management of arterial hypertension. European Heart Journal. 2018;39(33):3021–104. DOI: 10.1093/eurheartj/ehy339
30. Dahlöf B, Devereux RB, Kjeldsen SE, Julius S, Beevers G, de Faire U et al. Cardiovascular morbidity and mortality in the Losartan Intervention for Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Te Lancet. 2002;359(9311):995– 1003. DOI: 10.1016/S0140-6736(02)08089-3
31. Julius S, Kjeldsen SE, Weber M, Brunner HR, Ekman S, Hansson L et al. Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial. Te Lancet. 2004;363(9426):2022–31. DOI: 10.1016/S0140-6736(04)16451-9
32. ALLHAT Ofcers and Coordinators for the ALLHAT Collaborative Research Group. Te Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Atack Trial. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: Te Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Atack Trial (ALLHAT). JAMA. 2002;288(23):2981–97. PMID: 12479763
33. Dahlöf B, Sever PS, Poulter NR, Wedel H, Beevers DG, Caulfeld M et al. Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomised controlled trial. Te Lancet. 2005;366(9489):895–906. DOI: 10.1016/S0140-6736(05)67185-1
34. Zancheti A, Julius S, Kjeldsen S, McInnes GT, Hua T, Weber M et al. Outcomes in subgroups of hypertensive patients treated with regimens based on valsartan and amlodipine: an analysis of fndings from the VALUE trial: Journal of Hypertension. 2006;24(11):2163–8. DOI: 10.1097/01.hjh.0000249692.96488.46
35. Os I, Franco V, Kjeldsen SE, Manhem K, Devereux RB, Gerdts E et al. Effects of Losartan in Women with Hypertension and Lef Ventricular Hypertrophy: Results From the Losartan Intervention For Endpoint Reduction in Hypertension Study. Hypertension. 2008;51(4):1103– 8. DOI: 10.1161/HYPERTENSIONAHA.107.105296
36. Turnbull F, Woodward M, Neal B, Barzi F, Ninomiya T, Chalmers J et al. Do men and women respond differently to blood pressure-lowering treatment? Results of prospectively designed overviews of randomized trials. European Heart Journal. 2008;29(21):2669–80. DOI: 10.1093/eurheartj/ehn427
37. Skibitskiy V. V., Gorodetskaya E. V., Fendrikova A. V., Kudryashov E. A. Gender features of influence combination antihypertensive therapy on structural functional state of lef ventricular myocardium in patients with arterial hypertension and coronary heart disease. Problem of women health. 2015;10(1):10-9.
38. Denton KM, Hilliard LM, Tare M. Sex-Related Differences in Hypertension: Seek and Ye Shall Find. Hypertension. 2013;62(4):674–7. DOI: 10.1161/HYPERTENSIONAHA.113.00922
39. Glezer M. G. Te Use of Fixed Perindopril A/Amlodipine Combination Provides High Compliance to Terapy, Effective and Safe Arterial Pressure Lowering in Patients with Previous Inefferctive Terapy. Te POTENTIAL Program. Kardiologiia. 2015;55(12):17-24.
40. Scherer PE. Adipose Tissue: From Lipid Storage Compartment to Endocrine Organ. Diabetes. 2006;55(6):1537–45. DOI: 10.2337/db060263
41. Bermudez JA, Velásquez CM. Profle of free faty acids (FFA) in serum of young Colombians with obesity and metabolic syndrome. Archivos Latinoamericanos De Nutricion. 2014;64(4):248–57. PMID: 26336720
42. Scheen AJ, Krzesinski JM. Which place for thiazide and thiazide-like diuretics in patients with type 2 diabetes? Revue Medicale De Liege. 2018;73(4):176–82. PMID: 29676870
43. Wright JM, Musini VM, Gill R. First-line drugs for hypertension. Cochrane Database of Systematic Reviews. 2018; DOI: 10.1002/14651858.CD001841.pub3
44. Soldin OP, Matison DR. Sex Differences in Pharmacokinetics and Pharmacodynamics: Clinical Pharmacokinetics. 2009;48(3):143–57. DOI: 10.2165/00003088-200948030-00001
45. Rydberg DM, Mejyr S, Loikas D, Schenck-Gustafsson K, von Euler M, Malmström RE. Sex differences in spontaneous reports on adverse drug events for common antihypertensive drugs. European Journal of Clinical Pharmacology. 2018;74(9):1165–73. DOI: 10.1007/s00228-018-2480-y
Review
For citations:
Larina V.N., Orlov D.A. Antihypertensive therapy in male and female: are there sex differences in choice of drugs? Kardiologiia. 2019;59(1S):11-18. (In Russ.) https://doi.org/10.18087/cardio.2566
Views:
1609
Email this article 
Post a Comment 
